Dr Michel Sadelain was a surprise speaker at the Philly conference, and as always, it as a pleasure to meet him. David Davidson from Bluebird also spoke on his company's upcoming trials and future endeavors. I must admit, I was impressed by both speakers.
I want to give an update on something we have all been waiting for. The future for gene therapy is looking more promising than ever. The French patient is still well and transfusion independent. The trials currently being run at Sloan Kettering are still very early in the going, but the results are outpacing those of the French patient at this point in the trial, even though a low intensity chemo program was utilized. It was expected that the results would come at a slower pace than what has been seen so far. It is early on, and we should remember that results for the French patient were not released until 3 years into the trial.
I will also mention that the other company that will be running trials, Bluebird, will be recruiting patients internationally and will be paying expenses to the US for the trial. I was impressed by both gene therapy presentations. Over the next 25 years, we will be seeing a revolution in the treatment of genetic disorders.